Kalei­do, Cir­ius brace the IPO mar­ket seek­ing a com­bined $186M — de­spite bar­ri­ers at shut­down-mode SEC

As biotech stocks cel­e­brate a post-JPM ral­ly around the best ever start to the year, Kalei­do Bio­sciences and Cir­ius Ther­a­peu­tics have ap­plied to join the club de­spite a gov­ern­ment shut­down that’s frus­trat­ed a num­ber of ex­ecs try­ing to go pub­lic ear­ly this year.

Bank­ing on the promise of its plat­form tech to mod­u­late the func­tion and dis­tri­b­u­tion of the mi­crobes in the body, Kalei­do is seek­ing $100 mil­lion-plus, while Cir­ius’ ini­tial goal is set at $86 mil­lion for a fo­cused bet on a NASH pro­gram — at least for now.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER